The present invention relates to a gene and the coded protein thereof that is involved in the development of sequelae of local ischaemia. The new protein is a serine threonine protein kinase and provides a new therapeutic approach to the prophylaxis and therapy of apoplexy.

SYGNIS Bioscience GmbH &amp; Co. KG

Nucleic acid molecule encoding a neuronal serine-threonine protein kinase

Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight.

PROFESSIONAL DIETETICS S.p.A.

Professional Deitetics S.p.A.

, IT

Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

The degree of phosphorylation of serine and threonine residues of p100/p120 can affect the permeability of physiological barriers and also cell--cell adhesion properties. By changing physiological levels, various disorders can be treated, including multiple sclerosis, cancer, head injuries, oedema, stroke, inflammation and gastric ulcers. Furthermore, drugs can be allowed to pass across physiological barriers and the barriers can then be closed.

threonine/ictus

Nucleic acid molecule encoding a neuronal serine-threonine protein kinase

Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Modifying the permeability of physiological barriers

Il database di erbe medicinali più completo supportato dalla scienza